Silo Pharma Stock Price, News & Analysis

Silo Pharma, Inc. (Nasdaq: SILO) is described in its public disclosures as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The company focuses on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, while also managing a digital assets treasury strategy. Its therapeutic programs target underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

According to multiple company news releases, Silo Pharma’s portfolio includes SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for Post-Traumatic Stress Disorder (PTSD) and stress-induced anxiety, and SP-26, a ketamine implant candidate for fibromyalgia and chronic pain. The company also reports preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo states that its research is conducted in collaboration with leading universities and laboratories, and that SPC-15 development includes work with Columbia University and a soft mist nasal spray delivery system aimed at fast brain action.

Biopharmaceutical development focus

Silo Pharma characterizes itself as a developmental-stage biopharmaceutical company with a therapeutic focus on stress-induced psychiatric disorders, chronic pain, and CNS diseases. Public descriptions emphasize the development of traditional therapies and psychedelic treatments using novel formulations and drug delivery systems. The company highlights SPC-15 as a prophylactic intranasal treatment candidate for PTSD and anxiety, and has disclosed plans around Phase 1 clinical development, including open-label single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy subjects.

In its news releases, Silo Pharma notes that SPC-15 is being advanced through IND-enabling toxicology and toxicokinetic studies, bioanalytical and safety work in large animals, and drug-device studies of a formulation-specific nasal spray system. The company has also reported intellectual property expansion for SPC-15 technology in the United States, Australia, and Japan, and has stated its intention to pursue the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway for SPC-15.

Beyond SPC-15, Silo identifies SP-26 as a ketamine implant program for chronic pain and fibromyalgia, and references additional preclinical programs in Alzheimer’s disease and multiple sclerosis. These programs are presented as part of a pipeline designed to address conditions where existing treatment options are limited.

Cryptocurrency treasury and digital asset strategy

In addition to its biopharmaceutical activities, Silo Pharma publicly describes itself as a cryptocurrency treasury company. The company has disclosed the launch of a digital assets treasury strategy intended to participate in the growth and adoption of cryptocurrency and to expand and strengthen its capital resources. According to its news updates, this strategy combines staking for yield with a hedged overlay designed to reduce volatility in portfolio positions while maintaining upside potential.

Silo has reported initial cryptocurrency purchases in Bitcoin (BTC), Ethereum (ETH), Solana (SOL), and ResearchCoin (RSC). It has also announced an allocation to the Alphaledger/Simplify Target 12% Distribution Fund LLC (Alphaledger T12 Fund) as part of a real-world asset (RWA) investment strategy on the Solana blockchain. The company states that this allocation is intended to provide diversified exposure to tokenized real-world assets and to align with its approach to treasury diversification and digital asset integration.

To support its crypto treasury operations, Silo has disclosed a strategic agreement with Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations. The company indicates that Fireblocks is being used to provide institutional-grade infrastructure for custody, settlement, trading operations, and stablecoin payments related to its digital asset holdings.

Corporate structure, listing, and regulatory context

SEC filings identify Silo Pharma, Inc. as a Nevada corporation with its common stock listed on the Nasdaq Capital Market under the symbol SILO. The company’s filings classify it as a smaller reporting company and note that it is not an emerging growth company. In an 8-K filed on July 3, 2025, Silo reported receiving a Nasdaq notice of non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The filing states that this notice had no immediate effect on the listing or trading of the company’s common stock and outlines the time periods and potential use of a reverse stock split to regain compliance.

Silo has also reported various capital markets transactions and related registration activity. An 8-K dated October 1, 2025 describes a registered direct offering and concurrent private placement of common stock and warrants, with proceeds intended for working capital and general corporate purposes. A subsequent Form S-1 registration statement filed on October 28, 2025 relates to the resale of shares issuable upon exercise of warrants issued in that financing. These filings detail the terms of investor warrants, placement agent warrants, and related registration rights.

Strategic partnerships and intellectual property

Company news releases highlight several strategic relationships that support Silo Pharma’s dual focus. In biopharmaceutical development, Silo has announced a non-binding Letter of Intent with Allucent (US) LLC, a global clinical research organization (CRO), to provide clinical research services for planned Phase 1 studies of SPC-15. The contemplated scope includes clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling and simulation, and medical writing.

Silo has also reported that its SPC-15 program involves collaboration with Columbia University and that it is pursuing global patent protection for its technology, with patents granted in multiple jurisdictions. In the digital assets area, the company has disclosed an asset purchase agreement with MAVS Holdings LLC for certain software and domain names related to a web-based application marketed as “r2crypto.com,” as well as the acquisition of additional crypto- and holdings-related domain names.

To guide its cryptocurrency strategy, Silo’s board approved the establishment of a cryptocurrency advisory board. An 8-K filed on August 5, 2025 notes the appointment of Corwin Yu as the initial member of this advisory board under an advisory agreement that includes stock option compensation. The company describes this advisory structure as part of its broader crypto treasury strategy.

Governance and shareholder matters

Silo Pharma’s Definitive Proxy Statement (DEF 14A) dated September 5, 2025 outlines matters presented to shareholders at the 2025 annual meeting, including the election of directors, ratification of the independent registered public accounting firm, approval of a reverse stock split proposal, an amendment to the company’s equity incentive plan, and an adjournment proposal. An 8-K dated October 24, 2025 reports the voting results, including approval of an amendment to increase the number of shares reserved under the Amended and Restated 2020 Omnibus Equity Incentive Plan and shareholder authorization for a reverse stock split within a specified range, at the discretion of the board.

These governance disclosures provide context on how Silo manages equity compensation, capital structure flexibility, and auditor relationships as it pursues both its biopharmaceutical pipeline and its digital assets treasury activities.

Business profile summary

Based on its public descriptions, Silo Pharma, Inc. combines early-stage therapeutic development in psychiatry, pain, and CNS disorders with an actively managed cryptocurrency and tokenized asset treasury. Key elements of its profile include:

• Developmental-stage biopharmaceutical programs such as SPC-15 for PTSD and anxiety and SP-26 for fibromyalgia and chronic pain.
• Preclinical assets targeting Alzheimer’s disease and multiple sclerosis.
• Use of novel intranasal delivery systems and collaboration with academic institutions.
• A crypto treasury strategy involving Bitcoin, Ethereum, Solana, ResearchCoin, and tokenized real-world asset exposure via the Alphaledger T12 Fund.
• Engagement of Fireblocks for digital asset custody and infrastructure and establishment of a Crypto Advisory Board.
• Listing on the Nasdaq Capital Market under the symbol SILO, with recent capital raising activities and related SEC registrations.

Frequently Asked Questions

What does Silo Pharma, Inc. do?
According to its public disclosures, Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency treasury company. It develops novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments targeting stress-induced psychiatric disorders, chronic pain, and CNS diseases, while also operating a digital assets treasury strategy that includes cryptocurrency and tokenized real-world assets.

What are Silo Pharma’s main drug development programs?
Company news releases identify SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist for PTSD and stress-induced anxiety, as Silo’s lead candidate. Another program, SP-26, is described as a ketamine implant for fibromyalgia and chronic pain. Silo also reports preclinical assets aimed at Alzheimer’s disease and multiple sclerosis.

How is SPC-15 being developed?
Silo states that SPC-15 is being developed as an intranasal prophylactic treatment for PTSD and stress-induced anxiety using a soft mist nasal spray system for fast brain action. The company has reported completion of certain IND-enabling toxicology and toxicokinetic studies, large animal safety work, and a drug-device study, and has indicated plans for Phase 1 SAD and MAD studies in healthy subjects, supported by a contemplated collaboration with the CRO Allucent.

What is Silo Pharma’s cryptocurrency treasury strategy?
In its news updates and 8-K filings, Silo describes a digital assets treasury strategy launched in 2025. This strategy includes purchasing and managing cryptocurrencies such as Bitcoin, Ethereum, Solana, and ResearchCoin, combining staking for yield with a hedged overlay to manage volatility. The company also reports an allocation to the Alphaledger T12 Fund for exposure to tokenized real-world assets on the Solana blockchain.

Which partners and service providers does Silo work with?
Silo’s public communications reference several partners. In drug development, it has disclosed collaboration with Columbia University on SPC-15 and a non-binding letter of intent with Allucent to support Phase 1 clinical development. In digital assets, Silo has engaged Fireblocks for digital asset custody and infrastructure and selected the Alphaledger T12 Fund as a component of its RWA investment strategy. It has also entered into an asset purchase agreement with MAVS Holdings LLC for software and domain names related to a web-based crypto application.

On which exchange does Silo Pharma’s stock trade, and under what symbol?
SEC filings state that Silo Pharma’s common stock is listed on the Nasdaq Capital Market under the trading symbol SILO. The company has disclosed receiving a Nasdaq notice regarding minimum bid price compliance but has also stated that this notice had no immediate effect on the listing or trading of its common stock.

How does Silo Pharma describe its research collaborations?
Silo’s news releases state that its research is conducted in collaboration with leading universities and laboratories. Specific disclosures include a partnership with Columbia University related to SPC-15 and an agreement with the University of Maryland, Baltimore providing an evaluation license and an option to negotiate a new exclusive commercial license for intellectual property related to central nervous system-homing peptides.

What recent financing activities has Silo Pharma reported?
In 8-K filings and related press releases, Silo has described a registered direct offering and concurrent private placement completed on October 1, 2025, involving the sale of common stock and issuance of warrants to institutional investors, with H.C. Wainwright & Co. acting as placement agent. A subsequent Form S-1 registration statement covers the resale of shares issuable upon exercise of those warrants.

How is Silo Pharma addressing Nasdaq’s minimum bid price requirement?
An 8-K dated July 3, 2025 reports that Silo received a Nasdaq notification for non-compliance with the $1.00 minimum bid price requirement. The filing explains the compliance periods and notes that the company may consider options such as a reverse stock split. A later 8-K dated October 24, 2025 states that shareholders approved a proposal granting the board discretionary authority to implement a reverse stock split within a specified range, if deemed appropriate.